Hims & Hers Health, Inc. (NYSE:HIMS) Position Boosted by DnB Asset Management AS

DnB Asset Management AS increased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 116.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 138,665 shares of the company's stock after buying an additional 74,457 shares during the period. DnB Asset Management AS owned about 0.06% of Hims & Hers Health worth $3,353,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in HIMS. Main Management ETF Advisors LLC purchased a new position in Hims & Hers Health during the third quarter worth $672,000. Means Investment CO. Inc. boosted its holdings in shares of Hims & Hers Health by 23.5% during the fourth quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock worth $1,210,000 after purchasing an additional 9,508 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Hims & Hers Health by 102.0% in the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock valued at $5,349,000 after purchasing an additional 146,621 shares during the period. State of Alaska Department of Revenue acquired a new position in Hims & Hers Health in the fourth quarter valued at $2,628,000. Finally, Pacer Advisors Inc. purchased a new position in Hims & Hers Health during the fourth quarter worth about $374,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on HIMS shares. Canaccord Genuity Group lifted their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Truist Financial boosted their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a "hold" rating in a report on Wednesday, February 26th. Needham & Company LLC increased their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Morgan Stanley cut shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and boosted their price objective for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Finally, BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 target price on the stock. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $37.31.

Remove Ads

Hims & Hers Health Trading Down 7.4 %

NYSE:HIMS traded down $2.06 during mid-day trading on Friday, hitting $25.93. The company had a trading volume of 27,621,633 shares, compared to its average volume of 14,730,901. The business has a fifty day simple moving average of $39.82 and a 200-day simple moving average of $29.94. The firm has a market capitalization of $5.76 billion, a price-to-earnings ratio of 58.93 and a beta of 1.65. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 4,152 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now owns 157,345 shares in the company, valued at approximately $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $29.26, for a total value of $338,860.06. Following the completion of the transaction, the chief financial officer now directly owns 124,104 shares of the company's stock, valued at $3,631,283.04. This represents a 8.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,078,738 shares of company stock valued at $38,386,521. Corporate insiders own 17.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.